Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Relay Therapeutics, Inc. - Common Stock (NQ:RLAY)

8.415 -0.255 (-2.94%)
Streaming Delayed Price Updated: 12:12 PM EST, Feb 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 924,795
Open 8.730
Bid (Size) 8.400 (400)
Ask (Size) 8.430 (700)
Prev. Close 8.670
Today's Range 8.210 - 8.990
52wk Range 1.775 - 9.040
Shares Outstanding 121,613,181
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate
The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative... 
Via MarketMinute
Topics ETFs Government Initial Public Offering

Performance

YTD
+2.9%
+2.9%
1 Month
+7.1%
+7.1%
3 Month
+22.7%
+22.7%
6 Month
+138.4%
+138.4%
1 Year
+88.3%
+88.3%

More News

Read More
News headline image
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
Via Benzinga
News headline image
Preview: Relay Therapeutics's Earnings ↗
Via Benzinga
News headline image
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
From Equity Insider
Via GlobeNewswire
News headline image
Relay Therapeutics Director Sells $300,000 Worth of Shares. Here's Why Investors Shouldn't Panic. ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Beyond the Hype: AI’s Quiet Revolution in Niche Sectors Reshapes Industries from Medicine to Agriculture
Via TokenRing AI
Topics Artificial Intelligence Economy Emissions
News headline image
Relay Therapeutics Inc (NASDAQ:RLAY) Reports Q3 2025 Earnings Miss and Clinical Progress ↗
Via Chartmill
Topics Earnings
News headline image
Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week ↗
Via The Motley Fool
News headline image
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Medtronic To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Via Benzinga
News headline image
Relay (RLAY) Q2 Loss Narrows 41% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Relay Therapeutics, Inc. - Common Stock publicly traded?
Yes, Relay Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Relay Therapeutics, Inc. - Common Stock trade on?
Relay Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Relay Therapeutics, Inc. - Common Stock?
The ticker symbol for Relay Therapeutics, Inc. - Common Stock is RLAY on the Nasdaq Stock Market
What is the current price of Relay Therapeutics, Inc. - Common Stock?
The current price of Relay Therapeutics, Inc. - Common Stock is 8.415
When was Relay Therapeutics, Inc. - Common Stock last traded?
The last trade of Relay Therapeutics, Inc. - Common Stock was at 02/04/26 12:12 PM ET
What is the market capitalization of Relay Therapeutics, Inc. - Common Stock?
The market capitalization of Relay Therapeutics, Inc. - Common Stock is 1.02B
How many shares of Relay Therapeutics, Inc. - Common Stock are outstanding?
Relay Therapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.